Background: The possibility to survive with amyotrophic lateral sclerosis (ALS) varies considerably and survival extends from a few months to several years. A number of demographic and clinical factors predicting survival have been described; however, existing data are conflicting. We intended to predict patient survival in a population-based prospective cohort of ALS patients from variables known up to the time of diagnosis. Methods: Incident ALS patients diagnosed within three consecutive years were enrolled and regularly followed up. Candidate demographic and disease variables were analysed for survival probability using the Kaplan-Meier method. The Cox proportional hazard regression model was used to assess the influence of selected predictor variables on survival prognosis. Results: In the cohort of 193 patients (mean age 65.8, standard deviation 10.2 years), worse prognosis was independently predicted by older age, male gender, bulbar onset, probable or definite ALS according to El Escorial criteria, shorter interval between symptom onset and diagnosis, lower Functional Rating Scale, diagnosis of frontotemporal dementia, and living without a partner. Conclusions: Taking into account these predictor variables, an approximate survival prognosis of individual ALS patients at diagnosis seems feasible.

Keywords:
Amyotrophic lateral sclerosis, Survival, Prognostic factors, Population-based register
1.
Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing M: Amyotrophic lateral sclerosis. Lancet 2011;377:942-955.
2.
Ravits JM, La Spada AR: ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 2009;73:805-811.
3.
Del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, Van Belle G: Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60:813-819.
4.
Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A: Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology 2005;25:114-119.
5.
Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, Bottacchi E, Mutani R; Piemonte and Valle d'Aosta Register for ALS (PARALS): Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:99-103.
6.
Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, Lepore V, Simone IL, Lamberti P, Serlenga L, Logroscino G; SLAP Registry: Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2008;79:33-37.
7.
Rooney J, Byrne S, Heverin M, Corr B, Elamin M, Staines A, Goldacre B, Hardiman O: Survival analysis of Irish amyotrophic lateral sclerosis patients diagnosed from 1995-2010. PLoS One 2013;8:e74733.
8.
Elamin M, Phukan J, Bede P, Jordan N, Byrne S, Pender N, Hardiman O: Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 2011;76:1263-1269.
9.
Wolf J, Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, Grau AJ: Variability and prognostic relevance of different phenotypes in amyotrophic lateral sclerosis - data from a population-based registry. J Neurol Sci 2014;345:164-167.
10.
Pupillo E, Messina P, Logroscino G, Beghi E; SLALOM Group: Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol 2014;75:287-297.
11.
Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG; Eurals Consortium: Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009;10:310-323.
13.
Wolf J, Wöhrle JC, Palm F, Nix WA, Maschke M, Safer A, Becher H, Grau AJ: Incidence of amyotrophic lateral sclerosis in Rhineland-Palatinate, Germany. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:269-274.
14.
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE initiative: Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W163-W194.
15.
Ross MA, Miller RG, Berchert L, Parry G, Barohn RJ, Armon C, Bryan WW, Petajan J, Stromatt S, Goodpasture J, McGuire D: Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS study group. Neurology 1998;50:768-772.
16.
The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II study group. Arch Neurol 1996;53:141-147.
17.
Hosmer DW, Lemeshow S, May S: Applied Survival Analysis. Regression Modelling of Time to Event Data. Chapter 5: Model Building. Wiley, New York, 1999, p 168.
18.
Lee CT, Chiu YW, Wang KC, Hwang CS, Lin KH, Lee IT, Tsai CP: Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan. J Epidemiol 2013;23:35-40.
19.
Chio A, Calvo A, Moglia C, Mazzini L, Mora G; PARALS study group: Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011;82:740-746.
20.
Olney RK, Murphy J, Forshew D, Garwood E, Miller BL, Langmore S, Kohn MA, Lomen-Hoerth C: The effects of executive and behavioral dysfunction on the course of ALS. Neurology 2005;65:1774-1777.
21.
Hu WT, Shelnutt M, Wilson A, Yarab N, Kelly C, Grossman M, Libon DJ, Khan J, Lah JJ, Levey AI, Glass J: Behavior matters - cognitive predictors of survival in amyotrophic lateral sclerosis. PLoS One 2013;8:e57584.
22.
Mioshi E, Caga J, Lillo P, Hsieh S, Ramsey E, Devenney E, Hornberger M, Hodges JR, Kiernan MC: Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology 2014;82:149-155.
23.
Czaplinski A, Yen AA, Appel SH: Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol 2006;253:1428-1436.
24.
Beghi E, Millul A, Logroscino G, Vitelli E, Micheli A; SLALOM group: Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008;9:163-167.
25.
Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H: The ALSFRSr predicts survival time in an ALS clinic population. Neurology 2005;64:38-43.
26.
Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV: Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002;25:709-714.
27.
Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, Shinoda K, Sugino M, Hanafusa T: Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265-267.
28.
Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B: ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci 2008;275:69-73.
29.
Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, Preux PM, Couratier P: Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 2011;82:628-634.
30.
Jawaid A, Murthy SB, Wilson AM, Qureshi SU, Amro MJ, Wheaton M, Simpson E, Harati Y, Strutt AM, York MK, Schulz PE: A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler 2010;11:542-548.
31.
Shimizu T, Nagaoka U, Nakayama Y, Kawata A, Kugimoto C, Kuroiwa Y, Kawai M, Shimohata T, Nishizawa M, Mihara B, Arahata H, Fujii N, Namba R, Ito H, Imai T, Nobukuni K, Kondo K, Ogino M, Nakajima T, Komori T: Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler 2012;13:363-366.
32.
Czaplinski A, Yen AA, Appel SH: Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 2006;77:390-392.
33.
McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA: Survival in amyotrophic lateral sclerosis. The role of psychological factors. Arch Neurol 1994;51:17-23.
34.
Logroscino G, Traynor BJ, Hardiman O, Chio' A, Couratier P, Mitchell JD, Swingler RJ, Beghi E; EURALS: Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 2008;79:6-11.
35.
Scotton WJ, Scott KM, Moore DH, Almedom L, Wijesekera LC, Janssen A, Nigro C, Sakel M, Leigh PN, Shaw C, Al-Chalabi A: Prognostic categories for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;13:502-508.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.